blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2212349

EP2212349 - SYNTHETIC ANALOGUES OF NEURAL REGENERATION PEPTIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.06.2014
Database last updated on 19.10.2024
Most recent event   Tooltip24.07.2015Lapse of the patent in a contracting state
New state(s): BG		published on 26.08.2015  [2015/35]
Applicant(s)For all designated states
Curonz Holdings Company Limited
Level 1, 29 Nugent Street
Auckland / NZ
[2013/32]
Former [2012/13]For all designated states
Curonz Holdings Company Limited
Level 1, 29 Nugent Street
Auckland / NZ
Former [2010/31]For all designated states
Neuren Pharmaceuticals Limited
P.O. Box 9923
Newmarket 1149 Auckland / NZ
For all designated states
Harris, Paul William Richard
110 Christian Road Swanson
Waitakere City / NZ
For all designated states
Brimble, Margaret Anne
11A Torrance Street Epsom
Auckland / NZ
For all designated states
Sieg, Frank
20A Springfield Road Western Springs
Auckland / NZ
Inventor(s)01 / HARRIS, Paul, William, Richard
110 Christian Road
Swanson
Waitakere City / NZ
02 / BRIMBLE, Margaret, Anne
11A Torrance Street
Epsom
Auckland / NZ
03 / SIEG, Frank
20A Springfield Road
Western Springs
Auckland / NZ
 [2013/32]
Former [2010/31]01 / HARRIS, Paul, William, Richard
110 Christian Road Swanson
Waitakere City / NZ
02 / BRIMBLE, Margaret, Anne
11A Torrance Street Epsom
Auckland / NZ
03 / SIEG, Frank
20A Springfield Road Western Springs
Auckland / NZ
Representative(s)Kremer, Simon Mark
Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2013/32]Kremer, Simon Mark
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Former [2012/19]Kremer, Simon Mark
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Former [2012/13]Teall, Charlotte, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2010/33]Gowshall, Jonathan Vallance
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Former [2010/31]Dale, Charlotte
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 Munich / DE
Application number, filing date08840727.517.10.2008
[2010/31]
WO2008US11951
Priority number, dateUS20070999292P17.10.2007         Original published format: US 999292 P
US20070999503P18.10.2007         Original published format: US 999503 P
[2010/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009051844
Date:23.04.2009
Language:EN
[2009/17]
Type: A1 Application with search report 
No.:EP2212349
Date:04.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 23.04.2009 takes the place of the publication of the European patent application.
[2010/31]
Type: B1 Patent specification 
No.:EP2212349
Date:07.08.2013
Language:EN
[2013/32]
Search report(s)International search report - published on:US23.04.2009
(Supplementary) European search report - dispatched on:EP31.08.2010
ClassificationIPC:C07K7/08, C07K14/48
[2012/09]
CPC:
C07K7/08 (EP,US); A61P21/00 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/28 (EP); A61P43/00 (EP);
A61P9/10 (EP); C07K14/48 (EP,US); C07K7/06 (US);
A61K38/00 (EP,US); G01N2800/28 (US); G01N2800/2835 (US);
G01N2800/285 (US); G01N2800/2878 (US); G01N2800/2892 (US) (-)
Former IPC [2010/39]C07K14/475, C07K14/435, C07K7/08
Former IPC [2010/31]C07K14/475, C07K14/435
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/31]
TitleGerman:SYNTHETISCHE ANALOGA VON NEURALEN REGENERATIONSPEPTIDEN[2010/31]
English:SYNTHETIC ANALOGUES OF NEURAL REGENERATION PEPTIDES[2010/31]
French:ANALOGUES SYNTHÉTIQUES DE PEPTIDES DE RÉGÉNÉRATION NEURALE[2010/31]
Entry into regional phase17.05.2010National basic fee paid 
17.05.2010Search fee paid 
17.05.2010Designation fee(s) paid 
17.05.2010Examination fee paid 
Examination procedure17.05.2010Examination requested  [2010/31]
29.03.2011Amendment by applicant (claims and/or description)
20.07.2011Despatch of a communication from the examining division (Time limit: M06)
18.01.2012Reply to a communication from the examining division
02.05.2012Communication of intention to grant the patent
12.09.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.10.2012Communication of intention to grant the patent
08.04.2013Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
13.06.2013Fee for grant paid
13.06.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.07.2011
Opposition(s)08.05.2014No opposition filed within time limit [2014/29]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
13.06.2013Request for further processing filed
13.06.2013Full payment received (date of receipt of payment)
Request granted
08.07.2013Decision despatched
Fees paidRenewal fee
28.10.2010Renewal fee patent year 03
29.09.2011Renewal fee patent year 04
22.10.2012Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG07.08.2013
MC07.08.2013
RO07.08.2013
TR07.08.2013
NO07.11.2013
IS07.12.2013
[2015/35]
Former [2015/32]MC07.08.2013
RO07.08.2013
TR07.08.2013
NO07.11.2013
IS07.12.2013
Former [2014/25]MC07.08.2013
RO07.08.2013
NO07.11.2013
IS07.12.2013
Former [2014/22]RO07.08.2013
NO07.11.2013
IS07.12.2013
Former [2014/10]NO07.11.2013
IS07.12.2013
Former [2014/07]NO07.11.2013
Documents cited:Search[IA]WO2006121926  (NEUREN PHARMACEUTICALS LTD [NZ], et al) [I] 1,5-7 * page 6 - page 10; claims 1-16; table 1 * * page 15, line 21 - line 23 * [A] 2-4;
 [IA]WO2007011595  (NEUREN PHARMACEUTICALS LTD [NZ], et al) [I] 1,5-7 * page 3 - page 8; claims 1-10; sequences 1-29 * * page 13, line 35 - line 37 * [A] 2-4;
 [IA]WO03018754  (NEURONZ LTD [NZ], et al) [I] 1,5-7 * page 4 - page 5; claims 1-39; table 1 * [A] 2-4;
 [IA]WO2005042561  (NEUREN PHARMACEUTICALS LTD [NZ], et al) [I] 1,5-7 * page 4 - page 5; table 1 * * page 15, line 17 - line 25; claims 1-16 * * page 34, line 17 - line 19 * [A] 2-4;
 [A]  - GORBA T ET AL, "Neural regeneration protein is a novel chemoattractive and neuronal survival-promoting factor", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US LNKD- DOI:10.1016/J.YEXCR.2006.06.020, vol. 312, no. 16, ISSN 0014-4827, (20061001), pages 3060 - 3074, (20061001), XP024945194 [A] 1-13 * abstract *

DOI:   http://dx.doi.org/10.1016/j.yexcr.2006.06.020
International search[X]US2004180823  (PASQUALE ELENA B [US], et al);
 [A]US2005131212  (SIEG FRANK [NZ], et al)
by applicantWO9532003
    - PERRY TA; HOLLOWAY HW; WEERASURIYA A; MOUTON PR; DUFFY K; MATTINSON JA; GREIG NH, "Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy", EXP. NEUROLOGY, (2007), vol. 203, pages 293 - 303
    - JAKOBSEN J; LUNDBÆK K., "Neuropathy in experimental diabetes: an animal model.", BR. MED. J., (1976), vol. 2, pages 278 - 279
    - BELL RH; HYE RJ, "Animal models of diabetes mellitus: physiology and pathology.", J. SURG. RES., (1983), vol. 35, pages 433 - 460
    - MATTINGLY GE; FISCHER VW., "Peripheral neuropathy following prolonged exposure to streptozotocin-induced diabetes in rats: a teased nerve fiber study.", ACTA NEUROPATHOL., (1983), vol. 59, pages 133 - 138
    - SZKUDELSKI T, "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas.", PHYSIOL. RES., (2001), vol. 50, pages 536 - 546
    - SCHMEICHEL AM; SCHMELZER JD; LOW PA, "Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy.", DIABETES, (2003), vol. 52, pages 165 - 171
    - TOMLINSON DR; GARDINER NJ, "Glucose neurotoxicity.", NATURE NEUROSCI. REV., (2008), vol. 9, pages 36 - 45
    - WUARIN-BIERMAN L; ZAHND GR; KAUFMANN F; BURCKLEN L; ADLER J., "Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy", DIABETOLOGIA., (1987), vol. 30, pages 653 - 658
    - COURTEIX C; ESCHALIER A; LAVARENNE J., "Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain", PDIN., (1993), vol. 53, pages 81 - 88
    - DYCK PJ; GIANNINI C., "Pathologic alterations in the diabetic neuropathies of humans: a review", J.'NEUROPATHOL. EXP. NEURAL., (1996), vol. 55, pages 1181 - 1193
    - YAGIHASHI S; YAMAGISHI S-I; WADA R., "Pathology and pathogenic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms", DIAB. RES. CLIN. PRAC., (2007), vol. 77S, pages S 184 - S189
    - CHONG MS; HESTER J, "Diabetic painful neuropathy. Current and future treatment options", DRUGS, (2007), vol. 67, pages 569 - 585
    - QUASTHOFF S; HARTUNG HP, "Chemotherapy-induced peripheral neuropathy.", J. NEUROL., (2002), vol. 249, pages 9 - 17
    - WINDEBANK AJ; GRISOLD W., "Chemotherapy-induced neuropathy.", J. PERIPHER. NERV. SYST., (2008), vol. 13, pages 27 - 46
    - GREGG RW; MOLEPO JM; MONPETIT VJ; MIKAEL NZ; REDMOND D; GADIA M; STEWERT DJ., "Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.", J CLIN. ONCOL., (1992), vol. 10, pages 795 - 803
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.